Satisfactory therapeutic strategies for septic shock are still missing. Previously we found elevated levels of Wnt5A in patients with severe sepsis and septic shock. Wnt5A is released by activated macrophages but knowledge of its effects in the vascular system remains scant. Here we investigate the response of human coronary artery endothelial cells (HCAEC) to Wnt5A. We used a genome-wide differential expression approach to define novel targets regulated by Wnt5A. Gene ontology analysis of expression profiles revealed clusters of genes involved in actin cytoskeleton remodeling as the predominant targets of Wnt5A. Wnt5A targeted Rho-associated protein serine/threonine kinase (ROCK), leading to phosphorylation of LIM kinase-2 (LIMK2) and inactivation of the actin depolymerization factor cofilin-1 (CFL1). Functional experiments recording cytoskeletal rearrangements in living cells showed that Wnt5A enhanced stress fiber formation as a consequence of reduced actin depolymerization. The antagonist Wnt inhibitory factor 1 (WIF1) that specifically interferes with the WIF domain of Ryk receptors prevented actin polymerization. Wnt5A disrupted β-catenin and VE-cadherin adherens junctions forming inter-endothelial gaps. Functional experiments targeting the endothelial monolayer integrity and live recording of trans-endothelial resistance revealed enhanced permeability of Wnt5A-treated HCAEC. Ryk silencing completely prevented Wnt5A-induced endothelial hyperpermeability. Wnt5A decreased wound healing capacity of HCAEC monolayers; this was restored by the ROCK inhibitor Y-27632. Here we show that Wnt5A acts on the vascular endothelium causing enhanced permeability through Ryk interaction and downstream ROCK/LIMK2/CFL1 signaling. Wnt5A/Ryk signaling might provide novel therapeutic strategies to prevent capillary leakage in systemic inflammation and septic shock.
Endogenous inflammatory signaling molecules resulting from deregulated immune responses, can impair airway epithelial barrier function and predispose individuals with airway inflammatory diseases t...
Modulation of proinflammatory responses induced by IL-1β in human vascular endothelial cells (VEC) to reduce tissue damage is an emerging therapeutic strategy to prevent loss of organ function during local or systemic inflammatory diseases. The pathways and signalling molecules involved in IL-1β-induced vascular endothelial inflammation that could be potential targets for therapeutic modulation remain still poorly addressed. Our study applies a genome-wide differential expression approach to identify candidate genes regulated by IL-1β in primary VEC derived from coronary artery (HCAEC). Genes regulated 2-fold were subjected to GO analysis for potential drug targets. We identified HGF as one of the genes upregulated by IL-1β in HCAEC. Gene ontology analysis mapped HGF to a highly significant barrier-injuring and repair pathway, and to an inflammatory disease biomarker network enriched in IL-1β transcriptome in VEC. Further, IL-1β upregulated the expression of BDKRB2, CTSS, and SERT which are also critically involved in regulating VEC monolayer barrier function and can be targeted by therapeutic drugs. To our knowledge, the expression of CTSS and HGF was not yet reported being regulated by IL-1β in human immunocompetent VEC. These findings stimulate further studies to evaluate the critical roles and benefits of therapeutic targeting of BDKRB2, CTSS, HGF, and SERT with known inhibitors to modulate VEC barrier function, and in consequence, vascular leakage in IL-1β-driven inflammatory diseases.
25 January 2025 in Computers in Biology and Medicine